Alkem Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Alkem Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 5692, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.09% on the day, quoting at 25459.95. The Sensex is at 82146.86, down 0.16%. Alkem Laboratories Ltd has dropped around 1.08% in last one month.

Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has dropped around 6.32% in last one month and is currently quoting at 23051.85, up 0.49% on the day. The volume in the stock stood at 50099 shares today, compared to the daily average of 1.38 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 5716, up 1.11% on the day. Alkem Laboratories Ltd is up 23.4% in last one year as compared to a 12.93% spurt in NIFTY and a 14.67% spurt in the Nifty Pharma index.

The PE of the stock is 30.35 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

Alkem Laboratories announced that the United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) on 13 February, 2026 at the manufacturing facility of Enzene Biosciences (Enzene), a subsidiary of the Company in India located at Chakan, Pune.

At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved Zero observations related to data integrity - a critical validation of Enzene's quality systems and the reliability of regulatory filings.

Enzene is in the process of preparing and submitting its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions.

Powered by Capital Market - Live News

At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved zero observations related to data integrity ? a critical validation of Enzen?s quality systems and the reliability of regulatory filings.

Enzene is currently preparing its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions to address the observations.

Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.

The company?s consolidated net profit rose 2% to Rs 653.53 crore in Q3 FY26, compared with Rs 640.79 crore posted in Q3 FY26. Net sales jumped 10.7% YoY to Rs 3,736.82 crore in the quarter ended 31 December 2025.

Shares of Alkem Laboratories added 1.38% to currently trade at Rs 5,475.85 on the BSE.

Powered by Capital Market - Live News

Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 13 February 2026, inter alia, have recommended the interim dividend of Rs 43 per equity Share (i.e. 2150%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News